Form 6-K NOVO NORDISK A S For: May 03
- Wall Street ends first day of third quarter with solid rebound
- Tesla (TSLA) Delivered 254,695 EV Units in Q2, Below Consensus
- Goldman Sachs Warns Clients of More Equity Market Losses in Second Half of 2022
- Kohl's (KSS) Falls 15% After Ending Sale Talks With Franchise Group and Issuing Q2 Warning
- General Motors Warns It Has 95k Vehicles in Inventory Without Certain Components
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 3, 2022
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
DK- 2880, Bagsvaerd
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
|Form 20-F [X]||Form 40-F [ ]|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|Yes [ ]||No [X]|
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 3 May 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
|1||Details of the person discharging managerial responsibilities/person closely associated|
|a)||Name of the Board member/Executive/Associated Person||Novo Holdings A/S, Associated to Kasim Kutay|
|2||Reason for the notification|
|a)||Position/status||Member of the Board of Directors|
|b)||Initial notification/Amendment||Initial notification|
|3||Details of the issuer|
|a)||Name||Novo Nordisk A/S|
|4||Details of the transaction(s)|
|a)||Description of the financial instrument, type of instrument,||Shares|
|Identification code||Novo Nordisk B DK0060534915|
|b)||Nature of the transaction||Sale of shares|
|c)||Price(s) and volume(s)|
|DKK 808.51||4,207,500 shares|
|· Aggregated volume||4,207,500 shares|
|· Price||DKK 808.51|
|e)||Date of the transaction||2022-05-03|
|f)||Place of the transaction||Outside a trading venue|
Page 2 of 2
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
|Ambre Brown Morley||+45 3079 9289||[email protected]|
|Natalia Salomao Abrahao (US)||+1 848 304 1027||[email protected]|
|Daniel Muusmann Bohsen||+45 3075 2175||[email protected]|
|Ann Søndermølle Rendbæk||+45 3075 2253||[email protected]|
|David Heiberg Landsted||+45 3077 6915||[email protected]|
|Jacob Martin Wiborg Rode||+45 3075 5956||[email protected]|
|Mark Joseph Root (US)||+1 848 213 3219||[email protected]|
Novo Nordisk A/S
+45 4444 8888
24 25 67 90
|Company announcement No 42 / 2022|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
|Date: May 3, 2022||
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- July Penny Stocks Buying Guide, 3 Things to Know
- EnerGeo Alliance Urges Administration to Release Gulf of Mexico Permits in the Wake of the Proposed Five-Year Program Release
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!